Aberdeen Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Aberdeen Group’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-1,321,750	Closed	-$12.4M	–	1007
2026 Q2	$12.4M	Hold	1,321,750	–	–	0.02%	561
2026 Q1	$12.4M	Hold	1,321,750	–	–	0.02%	548
2025 Q4	$10.8M	Buy	1,321,750 +1,133,519	+602%	+$14M	0.02%	595
2025 Q3	$2.38M	Buy	188,231 +116,005	+161%	+$1.1M	﹤0.01%	765
2025 Q2	$498K	Buy	72,226 +45,332	+169%	+$329K	﹤0.01%	884
2025 Q1	$143K	Hold	26,894	–	–	﹤0.01%	932
2024 Q4	$317K	Hold	26,894	–	–	﹤0.01%	892
2024 Q3	$555K	Buy	26,894 +21,751	+423%	+$1.11M	﹤0.01%	850
2024 Q2	$233K	Hold	5,143	–	–	﹤0.01%	917
2024 Q1	$202K	Buy	+5,143	New	+$127K	﹤0.01%	929

Other funds holding CRBP

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return

Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

Aberdeen Group's CRBP Position: Q3 2026 in Review

Aberdeen Group sold out of Corbus Pharmaceuticals (CRBP) in Q3 2026, closing a stake of 1,321,750 shares — an estimated $12.4M sold.

Aberdeen Group first reported a position in CRBP in Q1 2024 and held it in 10 quarters. The position peaked at $12.4M in Q1 2026. 36 funds tracked by Wall St. Rank hold CRBP as of Q3 2026.

Aberdeen Group reported no remaining Corbus Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
Aberdeen Group sold 1,321,750 Corbus Pharmaceuticals shares in Q3 2026, an estimated $12.4M.
Aberdeen Group first reported a position in Corbus Pharmaceuticals in Q1 2024 and held it in 10 quarters.
Aberdeen Group's Corbus Pharmaceuticals position peaked at $12.4M in Q1 2026.
36 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2026.

Based on Aberdeen Group's 13F filing for Q3 2026, filed 6 Nov 2026.